A Novel PKCßII Inhibitor Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells Abstract #265

Introduction: Deregulation of the protein kinase C (PKC) signaling pathway has been implicated in tumor progression.
Aim(s): To investigate the antiproliferative and antisecretory effects of a novel PKC inhibitor (PI) in the human pancreatic endocrine cancer cell line, BON1.
Materials and methods: Cell viability was investigated by ATPlite kit, apoptosis by caspase 3/7 assay, GSK3-ß phosphorylation and Chromogranin A (CgA) secretion by ELISA, PKCßII localization by immunofluorescence, CgA expression by Western blot.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Maria Chiara Zatelli

To read results and conclusion, please login ...

Further abstracts you may be interested in

#629 Targeting Chaperone Activity and Chaperone Expression in Human GEP-NET Cells Can Repress Their Proliferation and Sensitize Them to Chemotherapy
Introduction: New approaches for better treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are acutely needed. Inhibitors of chaperone activity of heat shock protein 90 (Hsp90) seem to be promising agents but they upregulate cytoprotective chaperones Hsp70 and Hsp27.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Anna Demidkina
#1089 Role of TGF beta-1 in Regulating Pancreatic Neuroendocrine Tumor Cell Viability
Introduction: Neuroendocrine tumors (NETs) are heterogeneous neoplasms arising from neuroendocrine cells spread in the respiratory and gastro-entero-pancreatic epithelium. The role of transforming growth factor beta-1 (TGF b-1) in NET biology is largely unknown. TGF b-1 signaling pathway is tumor suppressive in most non-transformed epithelial cell lines. In contrast, many human carcinomas are refractory to the growth–inhibitory effects of TGF b-1.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: PhD student Simona Falletta
Keywords: pNET, TGF-b1, Everolimus
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#2684 Tumour-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumour Patients after Curative Resection
Introduction: Non-functional pancreatic neuroendocrine tumours (NF-PanNETs) are steadily increasing in prevalence and present several clinical challenges.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Wuhu Zhang
Authors: Zhang W, Wang W, ...
#2685 Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models
Introduction: Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Shan Wu
Authors: Wu S, Zhou J, Guo J, Hua Z, ...